FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

Risankizumab may be effective for achieving and sustaining super response among patients with moderate to severe psoriasis.

In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Can what you eat help calm psoriasis, a chronic inflammatory disease that affects the skin? It's identified by the ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Autoimmune disease hair loss can happen with alopecia areata, lupus, thyroid diseases, rheumatoid arthritis, Crohn’s disease, and scalp psoriasis. Each disease has different effects, ...

A gel-like sugar coating on immune cells has been found to play a starring role in psoriasis. Researchers discovered that immune cells shed this outer layer to help them exit the bloodstream and enter ...

Consuming a greater proportion of nutrients from plant sources may aid management of psoriasis symptoms, according to a study published online Feb. 19 in the European Journal of Nutrition.